Search Results

Suggested Topics within your search.
Refine Results
  1. 1
    RANK and RANK ligand expression in primary human osteosarcoma

    RANK and RANK ligand expression in primary human osteosarcoma by Daniel Branstetter, Kathy Rohrbach, Liya Huang, R Soriano, Mark Tometsko, Michelle Blake, Allison P. Jacob, William C. Dougall

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

    The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study by Socrates E. Papapoulos, Kurt Lippuner, Christian Roux, Celia J. F. Lin, David L. Kendler, E. Michael Lewiecki, Maria Luisa Brandi, E. J. Czerwiński, Edward Franek, P. Lakatos, C. Mautalén, Salvatore Minisola, Jean‐Yves Reginster, S. Jensen, Nadia Daizadeh, A. Wang, Marc A. Gavin, Cesar Libanati, Rachel B. Wagman, Henry G. Bone

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    T-cells and B-cells in osteoporosis

    T-cells and B-cells in osteoporosis by M. Neale Weitzmann

    Published 2014
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study

    Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study by Joy N. Tsai, Alexander V. Uihlein, Sherri‐Ann M. Burnett‐Bowie, Robert M. Neer, Yuli Zhu, Nicholas P. Derrico, Hang Lee, Mary Bouxsein, Benjamin Z. Leder

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials

    Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials by Ann V. Schwartz, Anne L. Schafer, Andrew Grey, Eric Vittinghoff, Lisa Palermo, Li‐Yung Lui, Robert B. Wallace, Steven R. Cummings, Dennis M. Black, Douglas C. Bauer, Ian R. Reid

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway

    Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway by Nagesha Guthalu Kondegowda, Rafael Fenutría, Ilana Pollack, Michael Orthofer, Adolfo García‐Ocaña, Josef Penninger, Rupangi C. Vasavada

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone

    Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone by Piotr Rutkowski, Stefano Ferrari, R. J. Grimer, Paul Stalley, P. D. S. Dijkstra, Andrzej Pieńkowski, Gualter Vaz, Jay S. Wunder, Leanne L. Seeger, Amy Feng, Zachary Roberts, Bruce Allen Bach

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

    Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 1... by Peyman Hadji, Νικόλαος Παπαϊωάννου, Evelien Gielen, Maurille Feudjo Tepie, E Zhang, Isolde Frieling, Piet Geusens, Polyzois Makras, Heinrich Resch, Gerd Möller, L. Kalouche-Khalil, Astrid Fahrleitner‐Pammer

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review

    The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review by Winnie Sohn, Mary Ann Simiens, Kelly Jaeger, Shauna Hutton, Graham Jang

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    Bisphosphonates and other bone agents for breast cancer

    Bisphosphonates and other bone agents for breast cancer by Brent O׳Carrigan, Matthew H. Wong, Melina L Willson, Martin R. Stockler, Nick Pavlakis, Annabel Goodwin

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease

    RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease by Tara Aghaloo, Simon Cheong, Olga Bezouglaia, Paul J. Kostenuik, Elisa Atti, Sarah Dry, Flávia Q. Pirih, Sotirios Tetradis

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review

    Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review by Marc Bienz, Fred Saad

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis

    Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis by Kenneth Poole, Graham M. Treece, Andrew H. Gee, Jacques P. Brown, Michael R. McClung, Andrea Wang, Cesar Libanati

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk

    RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosi... by Elizabeth J. Samelson, Paul D. Miller, Claus Christiansen, Nadia Daizadeh, Luanda Grazette, Mary S. Anthony, Ogo Egbuna, Andrea Wang, Suresh Siddhanti, Angela M. Cheung, Nathalie Franchimont, Douglas P. Kiel

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Denosumab: mechanism of action and clinical outcomes

    Denosumab: mechanism of action and clinical outcomes by David A. Hanley, Jonathan D. Adachi, Alan Bell, Vivien Brown

    Published 2012
    Get full text
    Revisão
    Save to List
    Saved in:
  16. 16
    Enhanced Immunoprotective Effects by Anti-IL-17 Antibody Translates to Improved Skeletal Parameters Under Estrogen Deficiency Compared With Anti-RANKL and Anti-TNF-α Antibodies

    Enhanced Immunoprotective Effects by Anti-IL-17 Antibody Translates to Improved Skeletal Parameters Under Estrogen Deficiency Compared With Anti-RANKL and Anti-TNF-α Antibodies by Abdul Malik Tyagi, Mohd Nizam Mansoori, Kamini Srivastava, Mohd Parvez Khan, Jyoti Kureel, Manisha Dixit, Priyanka Shukla, Ritu Trivedi, Naibedya Chattopadhyay, Divya Singh

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Giant-cell tumor of bone: treatment options and role of denosumab

    Giant-cell tumor of bone: treatment options and role of denosumab by Sant P. Chawla, Arun S. Singh, Neal Shiv Chawla

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  18. 18
    Painful Osseous Metastases

    Painful Osseous Metastases by Howard S. Smith

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis

    Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis by Linda Karlsson, Jonas Lundkvist, E Psachoulia, Michele Intorcia, O. Ström

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  20. 20
    Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications

    Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications by Javier de Castro, Rosario Dueñas García, Pilar Garrido, Dolores Isla, Bartomeu Massutí, Belén Blanca, Jorge Rodriguez Vazquez

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: